Mechanisms of Targeted Therapy Resistance Take a De-TOR

Cancer Cell

Volumn 24, Issue 3, 2013, Pages 284-286

  Gentry, Leanna R ^a   Martin, Timothy D ^a   Der, Channing J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN S6; PROTEIN SERINE THREONINE KINASE; SHORT HAIRPIN RNA; TRAMETINIB; VEMURAFENIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CULTURE; CELL MUTANT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DNA FLANKING REGION; DRUG RESISTANCE; DRUG SENSITIVITY; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENETIC MARKER; HUMAN; MELANOMA CELL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; THERAPY RESISTANCE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPROTEIN COMPLEXES; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TOR SERINE-THREONINE KINASES;

EID: 84883639819     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.021     Document Type: Short Survey

References (10)

1. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., Demanse D., De Buck S.S., Ru Q.C., Peters M., et al. J Clin Oncol. 2012, 30:282-290.
2. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. N.Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
3. Corcoran R.B., Rothenberg S.M., Hata A.N., Faber A.C., Piris A., Nazarian R.M., Brown R.D., Godfrey J.T., Winokur D., Walsh J., et al. Sci Transl Med. 2013, 5:196ra198.
4. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Nature 2002, 417:949-954.
5. Elkabets M., Vora S., Juric D., Morse N., Mino-Kenudson M., Muranen T., Tao J., Campos A.B., Rodon J., Ibrahim Y.H., et al. Sci Transl Med. 2013, 5:196ra199.
6. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., et al. N.Engl. J. Med. 2012, 367:107-114. METRIC Study Group.
7. Hauschild A., Grob J.J., Demidov L.V., Jouary T., Gutzmer R., Millward M., Rutkowski P., Blank C.U., Miller W.H., Kaempgen E., et al. Lancet 2012, 380:358-365.
8. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., et al. Mol. Cancer Ther. 2012, 11:317-328.
9. Salama A.K., Flaherty K.T. Clin Cancer Res. 2013, 19:4326-4334.
10. Sullivan R.J., Flaherty K.T. Eur. J. Cancer 2013, 49:1297-1304.